356 related articles for article (PubMed ID: 33086429)
21. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials.
Rao S; Jamal Siddiqi T; Khan MS; Michos ED; Navar AM; Wang TJ; Greene SJ; Prabhakaran D; Khera A; Pandey A
Prog Cardiovasc Dis; 2022; 73():48-55. PubMed ID: 35114251
[TBL] [Abstract][Full Text] [Related]
22. The strong case for government funding of a polypill for the secondary prevention of cardiovascular disease in New Zealand.
Selak V; Bullen C; Arroll B; Doughty R; Doughty R; Grey C; Harwood M; Crengle S
N Z Med J; 2019 Sep; 132(1502):77-83. PubMed ID: 31563929
[TBL] [Abstract][Full Text] [Related]
23. The Era of Polypills in the Management of Cardiovascular Diseases: Are We There Yet?
Khan AA; Siddiqui SA; Yasmin F; Abidi SM; Tariq R; Ahmed H; Murtaza N; Jawed F; Lashkerwala SS; Moin A; Shah SMI; Ullah I; Yousaf Z; Faizan M; Shahid MH
Curr Probl Cardiol; 2023 Aug; 48(8):101233. PubMed ID: 35490770
[TBL] [Abstract][Full Text] [Related]
24. Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.
Huffman MD; de Cates AN; Ebrahim S
JAMA; 2014 Nov; 312(19):2030-1. PubMed ID: 25399279
[TBL] [Abstract][Full Text] [Related]
25. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
26. Polypill treatments for cardiovascular diseases.
Webster R; Rodgers A
Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
[TBL] [Abstract][Full Text] [Related]
27. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
Despang P; Schikora M; Doehner W
Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
[TBL] [Abstract][Full Text] [Related]
28. Polypills for primary prevention of cardiovascular disease.
Chow CK; Meng Q
Nat Rev Cardiol; 2019 Oct; 16(10):602-611. PubMed ID: 31150009
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
Jahangiri R; Rezapour A; Malekzadeh R; Olyaeemanesh A; Roshandel G; Motevalian SA
PLoS One; 2022; 17(7):e0271908. PubMed ID: 35901100
[TBL] [Abstract][Full Text] [Related]
30. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
Mostaza JM; Suárez-Fernández C; Cosín-Sales J; Gómez-Huelgas R; Brotons C; Araujo FP; Borrayo G; Ruiz E;
BMC Cardiovasc Disord; 2022 Dec; 22(1):560. PubMed ID: 36550424
[TBL] [Abstract][Full Text] [Related]
32. Polypill: quo vadis?
Muscente F; De Caterina R
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
[TBL] [Abstract][Full Text] [Related]
33. Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials.
Mohamed MG; Osman M; Kheiri B; Saleem M; Lacasse A; Alkhouli M
Int J Cardiol; 2022 Aug; 360():91-98. PubMed ID: 35641323
[TBL] [Abstract][Full Text] [Related]
34. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
35. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.
Bahiru E; de Cates AN; Farr MR; Jarvis MC; Palla M; Rees K; Ebrahim S; Huffman MD
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD009868. PubMed ID: 28263370
[TBL] [Abstract][Full Text] [Related]
36. Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, A Randomized Clinical Trial.
Sadeghi M; Hoseini SG; Nateghi A; Sarrafzadegan N; Mansoorian M; Najafian J; Roohafza H
Curr Probl Cardiol; 2022 Jun; 47(6):100872. PubMed ID: 34016484
[TBL] [Abstract][Full Text] [Related]
37. Polypill: the evidence and the promise.
Lonn E; Yusuf S
Curr Opin Lipidol; 2009 Dec; 20(6):453-9. PubMed ID: 19884824
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
[TBL] [Abstract][Full Text] [Related]
39. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.
Castellano JM; Sanz G; Fernandez Ortiz A; Garrido E; Bansilal S; Fuster V
J Am Coll Cardiol; 2014 Aug; 64(6):613-21. PubMed ID: 25104532
[TBL] [Abstract][Full Text] [Related]
40. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
